Clinical Scorecard: Monitoring Intravitreal Injection Patients

At a Glance

Key Highlights

• Corneal nerve length and density decrease notably after the third intravitreal injection.
• Anti-VEGF injections can cause more corneal damage due to VEGF's role in nerve regeneration.
• Early detection of NK via corneal sensitivity testing and fluorescein staining is critical to prevent progression.

Guideline-Based Recommendations

Diagnosis

• Obtain detailed history of number and type of intravitreal injections.
• Assess risk factors including diabetes, stroke, autoimmune disease, dry eye disease, and prior ocular surgeries.
• Use the Ocular Surface Disease Index survey to evaluate vision-related symptoms.
• Perform corneal sensitivity testing using Cochet-Bonnet or Brill esthesiometers, cotton wisp, or unwaxed dental floss without prior eye drop instillation.
• Evaluate corneal fluorescein staining patterns focusing on central cornea and punctate epithelial defects.

Management

• Educate patients on the importance of regular follow-up to monitor for NK progression.
• Early intervention upon detection to prevent progression to stage 3 NK and vision loss.

Monitoring & Follow-up

• Regular screening of intravitreal injection patients for signs of NK using sensitivity testing and slit lamp examination.
• Monitor for conjunctival hyperemia, epithelial irregularity, stromal haze, punctate keratopathy, superficial vascularization, and stromal scarring.

Risks

• Progression to severe NK (stage 3) characterized by central corneal ulcers, stromal thinning, and melting requiring urgent care.
• Potential vision loss if NK is not detected and managed early.

Patient & Prescribing Data

Patients receiving multiple intravitreal injections, particularly anti-VEGF treatments.

Corneal nerve damage risk increases after the third injection; anti-VEGF agents pose higher risk due to interference with nerve healing.

Clinical Best Practices

• Do not instill eye drops before corneal sensitivity testing to avoid false results.
• Use quantitative corneal sensitivity grading scales for consistent monitoring.
• Inform patients about NK risks and signs to encourage adherence to follow-up appointments.
• Screen regularly to identify early NK and intervene promptly to prevent progression.

References

• Corneal nerve changes after intravitreal injections
• Role of VEGF in corneal nerve regeneration
• Diabetes as a risk factor for NK
• Stroke and autoimmune disease as risk factors for NK
• History of dry eye and ocular surgeries increasing NK risk
• Corneal Sensitivity Testing Grading Scale by Dr. Mark Milner
• Characteristics of stage 2 NK punctate epithelial defects
• Stage 3 NK clinical features and urgency
• Early NK signs on slit lamp exam
• Importance of patient education on follow-up
• Progression and treatment challenges of NK